Kodiak Sciences Inc
NASDAQ:KOD

  • LAST PRICE
    2.6100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    --- / 2.6100
  • Day Range
    ---
  • 52 Week Range
    1.3700
    7.7700
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
KOD
Kodiak Sciences Inc
137.3M
-0.7x
---
VIGL
Vigil Neuroscience Inc
134.8M
-1.6x
---
PDSB
PDS Biotechnology Corp
140.7M
-3.1x
---
ATYR
aTyr Pharma Inc
133.4M
-1.9x
---
ACTU
Actuate Therapeutics Inc
145.5M
0.0x
---
CNTX
Context Therapeutics Inc
147.0M
-1.8x
---
As of 2024-10-01

Company Information

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Contact Information

Headquarters
1200 PAGE MILL RDPALO ALTO, CA, United States 94304
Phone
650-281-0850
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Victor Perlroth
Chief Financial Officer, Executive Vice President, Secretary
John Borgeson
Independent Director
Robert Profusek
Independent Director
Felix Baker
Independent Director
Charles Bancroft

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$137.3M
Revenue (TTM)
$0.00
Shares Outstanding
52.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.34
EPS
$-3.77
Book Value
$5.06
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.